Fedratinib

Two intertwined, indirect mechanisms rather than a primary tubular or glomerular toxin. (1) Renally-influenced clearance: population pharmacokinetics identify creatinine clearance as a statistically significant covariate on fedratinib apparent clearance, so reduced kidney function raises drug exposure (AUC ~1.5-fold in moderate and ~1.9-fold in severe impairment), amplifying downstream toxicity unless the dose is cut. (2) GI-mediated fluid and electrolyte loss: frequent nausea, vomiting and diarrhea reduce intake and drive volume contraction with potassium and magnesium loss, which can precipitate prerenal/hemodynamic AKI. Serum-creatinine rises observed in trials may partly reflect this hemodynamic effect (and possibly altered tubular creatinine handling) rather than proven structural GFR loss. A separate, non-renal but thematically linked concern is thiamine (vitamin B1) deficiency and Wernicke encephalopathy, plausibly aggravated by the same GI losses/reduced intake — the drug's black-box warning.

Rather than a classic nephrotoxic syndrome, the picture is an at-risk patient: gastrointestinal upset (nausea, vomiting, diarrhea) with reduced oral intake and volume contraction, whose biochemical footprint is hypokalemia, hypomagnesemia and a rising serum creatinine (often modest and reversible with rehydration). In kidney impairment the higher fedratinib exposure can manifest as more pronounced GI and hematologic (anemia, thrombocytopenia) toxicity. The most feared associated event is Wernicke-type encephalopathy (confusion, ophthalmoplegia, ataxia) from thiamine deficiency — a neurologic emergency, not a renal one, but part of the same GI-loss theme.

Manage GI toxicity aggressively with antiemetics and antidiarrheals and by taking the dose with food; replete potassium and magnesium and restore intravascular volume for prerenal creatinine rises. Dose-interrupt or reduce for severe/persistent GI events, significant creatinine elevation, or cytopenias per label thresholds. For any encephalopathy, hold fedratinib immediately and give parenteral thiamine. In renal impairment, use the reduced dose and monitor exposure-driven toxicity (GI, hematologic); there is no specific antidote and no established renal-replacement removal strategy. Re-escalate cautiously once toxicity resolves.Lesion-level management framework

Mild renal impairment (CrCl 60-89 mL/min): no dose adjustment. Moderate impairment (CrCl 30-59 mL/min): the standard 400 mg once-daily dose may be used but with monitoring and dose reduction as needed, since exposure is ~37% higher on population PK. Severe impairment (CrCl 15-29 mL/min): reduce to 200 mg once daily — a dedicated phase 1 study found ~1.9-fold higher AUC. Not studied in end-stage renal disease/dialysis. Separately, reduce the dose (or avoid) with concomitant strong CYP3A4 inhibitors.

Not established and unlikely to be meaningfully dialyzable. Fedratinib is extensively protein-bound with a large volume of distribution and a long (~41 h) effective half-life; the dedicated impairment study did not identify hemodialysis as a clearance route, and no dosing recommendation exists for dialysis patients. Dosing is driven by exposure and tolerability, not by dialytic removal.

Distinguish a prerenal/hemodynamic creatinine rise from GI volume loss (improves promptly with rehydration) from true intrinsic AKI. Consider that fedratinib's reported serum-creatinine elevations may be a laboratory or hemodynamic signal rather than a fall in true GFR — confirm with cystatin C or the trajectory if the clinical picture does not fit. Separate thiamine-deficiency Wernicke encephalopathy from other causes of altered mental status (hepatic encephalopathy, sepsis, CNS disease). Attribute electrolyte disturbances to GI losses and concomitant drugs rather than to a specific tubulopathy, since fedratinib is not a recognized direct tubular toxin. Anemia and thrombocytopenia are usually disease- or exposure-related cytopenias, not a renal process.